Patients with early-stage non-small-cell lung cancer undergo surgery with curative intent. Many of these patients relapse and, therefore, adjuvant therapies are important for improving survival of these patients. Adjuvant chemotherapy has been established and increases the 5-year survival rate. Here, we discuss systemic treatment strategies for further improving outcome of patients with completely resected non-small-cell lung cancer.
Keywords: Adjuvant chemotherapy; Immunotherapy; Prognosis; Surgery; Targeted therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.